REGENERON PHARMACEUTICALS, INC.

(REGN)
  Report
Delayed Nasdaq  -  05/23 04:00:01 pm EDT
681.91 USD   +3.14%
05/23SVB Securities Initiates Regeneron Pharmaceuticals at Outperform with $738 Price Target
MT
05/23Fda approves dupixent (dupilumab) as first treatment for adults and children aged 12 and older with eosinophilic esophagitis
AQ
05/23Evkeeza (evinacumab) phase 3 trial demonstrates 48% ldl-c reduction in children with ultra-rare form of high cholesterol
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Regeneron Pharmaceuticals, Ultragenyx Pharmaceutical Strike Commercialization Deal for Evkeeza Medicine

01/07/2022 | 07:40am EDT


ę MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
REGENERON PHARMACEUTICALS, INC. 3.14% 681.91 Delayed Quote.7.98%
ULTRAGENYX PHARMACEUTICAL INC. -1.26% 47.94 Delayed Quote.-42.99%
All news about REGENERON PHARMACEUTICALS, INC.
05/23SVB Securities Initiates Regeneron Pharmaceuticals at Outperform with $738 Price Target
MT
05/23Fda approves dupixent (dupilumab) as first treatment for adults and children aged 12 an..
AQ
05/23Evkeeza (evinacumab) phase 3 trial demonstrates 48% ldl-c reduction in children with ul..
AQ
05/23FDA approves Dupixent« (dupilumab) as first treatment for adults and children aged 12 ..
AQ
05/23SVB Securities Initiates Regeneron Pharmaceuticals at Outperform With $738 Price Target
MT
05/23Regeneron's Phase 3 Trial Data Shows Positive Results for Potential Treatment of Rare H..
MT
05/21Evkeeza« (evinacumab) Phase 3 Trial Demonstrates 48% LDL-C Reduction in Children with U..
PR
05/20Regeneron, Sanofi Receive US FDA Approval of Dupixent for Eosinophilic Esophagitis
MT
05/20Sanofi's Dupixent wins U.S. approval for bigger use
RE
05/20FDA Grants Regeneron Approval for Dupixent in Inflammatory Disorder Treatment
DJ
More news
Analyst Recommendations on REGENERON PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2022 11 835 M - -
Net income 2022 4 041 M - -
Net cash 2022 8 670 M - -
P/E ratio 2022 18,4x
Yield 2022 -
Capitalization 73 473 M 73 473 M -
EV / Sales 2022 5,48x
EV / Sales 2023 4,84x
Nbr of Employees 10 492
Free-Float 81,0%
Chart REGENERON PHARMACEUTICALS, INC.
Duration : Period :
Regeneron Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends REGENERON PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Last Close Price 681,91 $
Average target price 691,67 $
Spread / Average Target 1,43%
EPS Revisions
Managers and Directors
Leonard S. Schleifer Chairman, Co-President & CEO
George Damis Yancopoulos Co-President, Director & Chief Scientific Officer
Robert E. Landry Chief Financial Officer & Executive VP-Finance
P. Roy Vagelos Chairman
Neil Stahl SVP-Preclinical Development
Sector and Competitors
1st jan.Capi. (M$)
REGENERON PHARMACEUTICALS, INC.7.98%73 473
GILEAD SCIENCES, INC.-12.33%79 850
VERTEX PHARMACEUTICALS22.20%68 632
WUXI APPTEC CO., LTD.-17.77%42 378
BIONTECH SE-36.69%39 666
GENMAB A/S-18.02%20 276